Results 61 to 70 of about 14,826 (163)

Pharmacokinetic non-interaction analysis in a fixed-dose formulation in combination of atorvastatin and ezetimibe

Frontiers in Pharmacology, 2014
Recent clinical research has shown that atorvastatin in combination with cholesterol absorption inhibitor ezetimibe significantly reduces LDL-C level in patients with hypercholesterolemia, showing a superior lipid-lowering efficacy compared to statin ...
Omar ePatiño-Rodríguez, Irma eTorres-Roque, Maricela eMartínez-Delgado, Abraham eEscobedo-Moratilla, José ePérez-Urizar   +4 more
doaj   +1 more source

Tirzepatide for Excess Weight in Adults With Type 1 Diabetes Using MiniMed 780G

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8709-8713, September 2026.
Michelantonio De Fano, Rachele Tortoriello, Stefania Rucco, Sofia Corio, Marcello Manco, Edoardo Guerrini, Francesca Porcellati   +6 more
wiley   +1 more source

The changing epidemiology of human type 2 diabetes–associated atherosclerosis: Pathophysiological mechanisms and emerging treatment possibilities

Journal of Internal Medicine, Volume 300, Issue 2, Page 131-152, August 2026.
Abstract Type 2 diabetes (T2D) is a major global health concern strongly associated with atherosclerosis and subsequent macrovascular complications. These complications are the leading cause of death among T2D patients. Despite a decline in cardiovascular events over the last decade, individuals with T2D still have an approximately doubled risk ...
Dania Al‐Sharify, Jiangming Sun, Andreas Edsfeldt   +2 more
wiley   +1 more source

Intestinal Source Control of Lipid Metabolism by Enzyme‐Probiotic Encapsulated, Spatiotemporal Crosslinked, and Small Intestine‐Adhesive Hydrogel Microspheres

Advanced Science, Volume 13, Issue 39, 13 July 2026.
A thiol‐modified alginate hydrogel microsphere‐encapsulated enzyme‐probiotic biohybrid (AKK‐COD) system has been developed to address the spatiotemporal delivery and colonization challenges of small intestine‐targeted probiotic for lipid metabolism regulation. The system exerts sequential functions of intragastric protection, small intestinal adhesion,
Xiaolin Wu, Weiwen Liang, Siqi He, Guangyuan Chen, Hui Zhou, Xinglong Wang, Yifei Li, Dingcai Wu, Bingna Zheng, Ruoxu Dou, Rongkang Huang   +10 more
wiley   +1 more source

Species Differences in Ezetimibe Glucuronidation

Metabolites
Background: Peclinical and clinical studies have revealed that ezetimibe, an approved cholesterol-absorption inhibitor, is rapidly and extensively metabolized to a more potent metabolite, ezetimibe glucuronide.
Shalom Emmanuel, Eric A. Asare, Ting Du, Huan Xie, Dong Liang, Song Gao   +5 more
doaj   +1 more source

Blockade of cholesterol absorption by ezetimibe reveals a complex homeostatic network in enterocytes

Journal of Lipid Research, 2012
Enterocyte cholesterol homeostasis reflects aggregated rates of sterol synthesis, efflux, and uptake from plasma and gut lumen. Cholesterol synthesis and LDL uptake are coordinately regulated by sterol regulatory element-binding proteins (SREBP), whereas
Luke J. Engelking, Matthew R. McFarlane, Christina K. Li, Guosheng Liang   +3 more
doaj   +1 more source

Combination of Ezetimibe and Garlic Reduces Serum Lipids and Intestinal Niemann-Pick C1-like 1 Expression More Effectively in Hypercholesterolemic Mice

Avicenna Journal of Medical Biochemistry, 2015
Background Combination therapy plays an important role in the management of cardiovascular disease (CVD). Objectives The aim of this experiment was to study the influence of garlic combined with ezetimibe ...
Mohammadi, Vafaei, Nabi Moradi, Ahmadi, Pourjafar, Abbasi Oshaghi   +5 more
doaj   +1 more source

The lipid-lowering effect of ezetimibe in pure vegetarians

Journal of Lipid Research, 2006
Results of previous studies have shown that ezetimibe (10 mg/day) reduces LDL cholesterol in patients with mild hypercholesterolemia on a normal-cholesterol diet (dietary intake of 200–500 mg/day) by 16–22%.
Jacob J. Clarenbach, Michael Reber, Dieter Lütjohann, Klaus von Bergmann, Thomas Sudhop   +4 more
doaj   +1 more source

Ezetimibe and the risk of new-onset type 2 diabetes: a systematic review and meta-analysis

Annals of Medicine
Background Statins reduce cardiovascular risk but may increase new-onset type 2 diabetes mellitus (NO-T2DM). Ezetimibe, a cholesterol absorption inhibitor, is often added to statins to improve lipid control, yet its impact on NO-T2DM remains uncertain ...
Areej S. Albawa’neh, Mais N. Alqasrawi, Zeina N. Al-Mahayri, Amal Albawaana, Gamila Ahmed, Rami H. Al-Rifai, Bassam R. Ali   +6 more
doaj   +1 more source

Ezetimibe (Zetia) [PDF]

Medical Journal Armed Forces India, 2004
openaire   +2 more sources